AORTIC COMPLIANCE IN YOUNG-PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

被引:81
|
作者
LEHMANN, ED
WATTS, GF
FATEMILANGROUDI, B
GOSLING, RG
机构
[1] UNIV LONDON,GUYS & ST THOMAS HOSP,UNITED MED & DENT SCH,DIV RADIOL SCI,LONDON,ENGLAND
[2] UNIV LONDON,GUYS & ST THOMAS HOSP,UNITED MED & DENT SCH,LONDON,ENGLAND
关键词
AORTIC COMPLIANCE; AORTIC DISTENSIBILITY; FAMILIAL HYPERCHOLESTEROLEMIA;
D O I
10.1042/cs0830717
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. Aortic compliance and plasma lipid and lipoprotein levels were measured in 20 young patients with heterozygous familial hypercholesterolaemia and in 20 age- and sex-matched control subjects. 2. Patients with familial hypercholesterolaemia had significantly higher plasma cholesterol, low-density lipoprotein-cholesterol and triacylglycerol levels than control subjects (P<0.001, P<0.001 and P<0.005, respectively). The patients with familial hypercholesterolaemia also had significantly more compliant (distensible) aortas than the control subjects (P<0.001), a significant inverse correlation being observed between compliance and age (r = -0.73, P<0.001) and between compliance and mean blood pressure (r = -0.60, P<0.005). 3. When the effects of age and sex on aortic compliance were corrected for, the blood pressure effect disappeared, significant correlations being observed between normalized compliance and cholesterol (r = 0.50, P<0.03), low-density lipoprotein-cholesterol (r = 0.54, P<0.01), high-density lipoprotein-cholesterol (r = -0.44, P<0.05), low-density lipoprotein-/high-density lipoprotein-cholesterol ratio (r = 0.60, P<0.006) and duration of disease (r = 0.67, P<0.002). Multivariate regression analysis showed that the low-density lipoprotein-/high-density lipoprotein-cholesterol ratio (P<0.03) and duration of disease (P<0.04) were the best predictors of normalized compliance. 4. We suggest that the measurement of aortic compliance in young patients with familial hypercholesterolaemia may potentially be a useful, non-invasive, research tool for assessing their susceptibility to atheroma.
引用
收藏
页码:717 / 721
页数:5
相关论文
共 50 条
  • [31] Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
    Hartgers, Merel L.
    Defesche, Joep C.
    Langslet, Gisle
    Hopkins, Paul N.
    Kastelein, John J. P.
    Baccara-Dinet, Marie T.
    Seiz, Werner
    Hamon, Sara
    Banerjee, Poulabi
    Stefanutti, Claudia
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (02) : 390 - 396
  • [32] Aortic Valve Calcification and Coronary Plaque Morphology in Japanese Heterozygous Familial Hypercholesterolemia Patients With Gene Mutation
    Yamamoto, Aya
    Sakai, Akiko
    Sekiguchi, Haruki
    Sato, Kayoko
    Fukushima, Kenji
    Sakai, Syuji
    Hagiwara, Nobuhisa
    CIRCULATION, 2017, 136
  • [33] MECHANISMS OF MINERALIZATION OF AORTIC XENOBIOPROSTHESIS IN YOUNG-PATIENTS
    TSUKERMAN, GI
    BARBARASH, LS
    YAROSHINSKY, YN
    BYKOVA, VA
    BLAGOVESHCHENSKAYA, RP
    FURSOV, BA
    LEONTYEV, VK
    SHRAIBER, AA
    BUCHEROVA, SG
    KARDIOLOGIYA, 1985, 25 (07) : 45 - &
  • [34] LONG-TERM TREATMENT OF YOUNG-PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA WITH COLESTIPOL - PLASMA-LEVELS OF MINERALS AND VITAMINS
    SCHLIERF, G
    VOGEL, G
    KOHLMEIER, M
    VUILLEUMIER, JP
    HUPPE, R
    SCHMIDTGAYK, H
    KLINISCHE WOCHENSCHRIFT, 1985, 63 (17): : 802 - 806
  • [35] AORTIC STENOSIS IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN PROLONGED TREATMENT WITH STATINS.
    Marco-Benedi, V.
    Casado-Dominguez, J. M.
    Villa Pobo, R.
    Mateo-Gallego, R.
    Perez Calahorra, S.
    Sanchez-Hernandez, R.
    Blanco Nuez, M.
    Ortega-Martinez de Victoria, E.
    Amor Fernandez, A. J.
    Zambon, D.
    Sitges Carreno, M.
    Pedro-Botet, J.
    Puzo, J.
    Villarroel, T.
    Civeira, F.
    ATHEROSCLEROSIS, 2019, 287 : E182 - E182
  • [36] AORTIC ELASTIC PROPERTIES OF FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS
    Kaya, Esra
    Kayikcioglu, Meral
    Payzin, Serdar
    Can, Levent Hurkan
    ATHEROSCLEROSIS, 2017, 263 : E234 - E235
  • [37] Arterial characteristics in patients with heterozygous familial hypercholesterolemia: effect of rosuvastatin
    Masoura, C.
    Pitsavos, C.
    Skoumas, I.
    Aznaouridis, K.
    Vlachopoulos, C.
    Papadimitriou, L.
    Raftopoulou, S.
    Giotsas, N.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2008, 29 : 615 - 615
  • [38] Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
    Wozniak, Ewelina
    Broncel, Marlena
    Wozniak, Agnieszka
    Satala, Joanna
    Pawlos, Agnieszka
    Bukowska, Bozena
    Gorzelak-Pabis, Paulina
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [39] Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia
    Hopkins, PN
    Stephenson, S
    Wu, LL
    Riley, WA
    Xin, YP
    Hunt, SC
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (05): : 547 - 553
  • [40] Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia
    Merran Macpherson
    Bengt Hamrén
    Marjet J. A. M. Braamskamp
    John J. P. Kastelein
    Torbjörn Lundström
    Paul D. Martin
    European Journal of Clinical Pharmacology, 2016, 72 : 19 - 27